How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Do you agree with the proposal not to update the guideline?

  • Question on Consultation

    Do you have any comments on areas excluded from the scope of the guideline?

  • Question on Consultation

    Do you have any comments on equality issues?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Summary of evidence for 2019 surveillance of menopause (2015) NICE guideline NG23

Closed for comments This consultation ended on at   Request commenting lead permission

Research recommendations

What is the safety and effectiveness of alternatives to systemic HRT as treatments for menopausal symptoms in women who have had treatment for breast cancer?

  • No new evidence relevant to the research recommendation was found and no ongoing studies were identified.

What is the impact of systemic HRT usage in women with a previous diagnosis of breast cancer for the risk of breast cancer reoccurrence, mortality or tumour aggression?

  • No new evidence relevant to the research recommendation was found and no ongoing studies were identified.

How does the preparation of HRT affect the risk of venous thromboembolism (VTE)?

What is the difference in the risk of breast cancer in menopausal women on HRT with progesterone, progestogen or selective oestrogen receptor modulators?

  • New research relevant to the risk of breast cancer was identified but does not clearly answer this research recommendation.

What is the impact of oestradiol in combination with the levonorgestrel-releasing intrauterine system (LNG-IUS) on the risk of breast cancer and venous thromboembolism (VTE)?

  • No new evidence relevant to the research recommendation was found and no ongoing studies were identified.

What are the effects of early HRT use on the risk of dementia?

  • New research relevant to the risk of dementia was identified but does not clearly answer this research recommendation.

What are the main clinical manifestations of premature ovarian insufficiency and the short- and long-term impact of the most common therapeutic interventions?

  • No new evidence relevant to the research recommendation was found and no ongoing studies were identified.